A study conducted on mucosal gene expression profiles of IBD patients showed that the MAPK pathway, in particular MEK, was strongly activated in CD patients, and the application of selective MEK1/2 inhibitors could improve the pathological condition even in patients who are non-responders to anti-TNF-α biologic drugs [39]. The gene discussed is MAP2K1; the disease is inflammatory bowel disease.